Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children.

PLoS One · 2011 · PMC3142124 · PMID 21799810

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

marginally significantp = 0.09so close (0.05 < p ≤ 0.1)

The difference in the failure functions was marginally significant (IR first ep = 0.00342 for Inflexal®V and 0.00179 for PEV3B respectively, p = 0.09; HR first ep = 0.48 [0.20–1.15]) ( Figure 4 ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.